Altamira Expands Bentrio® Distribution to Sweden and Denmark with Pharma Nordic

Today, Altamira Therapeutics Ltd. announced that Sweden and Denmark will now be included in the zone covered by their exclusive distribution agreement for Bentrio®. This arrangement was reached with Pharma Nordic AS ("Pharma Nordic"), its Norwegian partner. Pharma Nordic plans to offer the Bentrio nasal spray for the prevention and treatment of allergic rhinitis in these two more Scandinavian nations the following year, after its successful debut in Norway earlier this year.

The Chairman and CEO of Altamira Medica, Thomas Meyer, stated, "We have been very pleased and impressed by Pharma Nordic's market launch activities and success in Norway." Therefore, it would be in everyone's best interests to move our cooperation's geographic reach up to include Sweden and Denmark in the following phase. We are eager to make Bentrio available to patients in these two more nations and to keep working with Pharma Nordic to establish the product as one of the top brands in Scandinavia for the treatment of allergic rhinitis.

Bent Andreassen, CEO of Pharma Nordic, said, "We received very positive responses to Bentrio from members of the medical community and allergic rhinitis sufferers in Norway, demonstrating a clear need for effective and safe treatment alternatives." "Bentrio is uniquely positioned to address patients' unmet needs with its drug-free and preservative-free formulation and strong data on efficacy and tolerability." We can't wait to introduce Bentrio to the Swedish and Danish markets and go on with the roll-out in Norway. These two markets have a lot in common, most notably a love of cutting-edge medical technology.